Introduction The present web-based national survey aims to assess the clinician's perspective... more Introduction The present web-based national survey aims to assess the clinician's perspective toward (1) the indications to perform positron emission tomography/computed tomography (PET/CT) in cancer patients, (2) the utility of the interaction with the referring nuclear medicine physician, and (3) their perception of the clarity, usefulness, and the impact of the PET/CT report. Methods We conducted a prospective web-based survey consisting of 31 multiple-choice questions and an open-text field. The questionnaire was administered to Italian clinicians or surgeons who managed oncological patients. Data were analyzed using standard diagrams and the values were expressed as numbers (percentages). Results A total of 373 physicians completed the questionnaire. Among the 360 responses finally included in the analysis, the majority came from radiation oncologists (46%), followed by oncologists. For half of the respondents (53%), indications to perform PET/CT examination were “often” cl...
Abstract: FAPI-based radiopharmaceuticals are a novel class of tracers, mainly used for PET imagi... more Abstract: FAPI-based radiopharmaceuticals are a novel class of tracers, mainly used for PET imaging, which have demonstrated several advantages over [18F]FDG, especially in the case of low-grade or well-differentiated tumors. We conducted this systematic review to evaluate all the studies where a head-to-head comparison had been performed to explore the potential utility of FAPI tracers in clinical practice. FAPI-based radiopharmaceuticals have shown promising results globally, in particular in detecting peritoneal carcinomatosis, but studies with wider populations are needed to better understand all the advantages of these new radiopharmaceuticals.
In the era of precision medicine, the optimization of oncological patient management with early a... more In the era of precision medicine, the optimization of oncological patient management with early and accurate tumor response assessment is crucial. In this scenario, [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has gained an important role in providing prognostically relevant information. The first PET-based scoring system proposed in 1999 was the well-known European Organization for Research and Treatment of Cancer (EORTC) criteria. From that moment on and over the last 20 years, several PET/CT criteria have emerged and have been adapted to enhance the response assessment for specific tumor types and/or therapies, with only a few of them endorsed by guidelines. In this literature systematic review, we aimed to list and discuss the most relevant PET/CT criteria proposed for solid and non-solid [18F]FDG-avid tumors. A literature search extended until November 2022 on the PubMed/MEDLINE database was conducted. The criteria used to assess ...
Background: in recent years, the role of positron emission tomography (PET) and PET/computed tomo... more Background: in recent years, the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide variety of pathological conditions. This review aims to collect and review PET criteria developed for interpretation and treatment response assessment in cases of non-[18F]fluorodeoxyglucose ([18F]FDG) imaging in oncology. Methods: A wide literature search of the PubMed/MEDLINE, Scopus and Google Scholar databases was made to find relevant published articles about non-[18F]FDG PET response criteria. Results: The comprehensive computer literature search revealed 183 articles. On reviewing the titles and abstracts, 149 articles were excluded because the reported data were not within the field of interest. Finally, 34 articles were selected and retrieved in full-text versions. Conclusions: available criteria are a promising tool for the interpretation of non-FDG PET scans, but also to assess the response to therapy and ther...
Introduction The present web-based national survey aims to assess the clinician's perspective... more Introduction The present web-based national survey aims to assess the clinician's perspective toward (1) the indications to perform positron emission tomography/computed tomography (PET/CT) in cancer patients, (2) the utility of the interaction with the referring nuclear medicine physician, and (3) their perception of the clarity, usefulness, and the impact of the PET/CT report. Methods We conducted a prospective web-based survey consisting of 31 multiple-choice questions and an open-text field. The questionnaire was administered to Italian clinicians or surgeons who managed oncological patients. Data were analyzed using standard diagrams and the values were expressed as numbers (percentages). Results A total of 373 physicians completed the questionnaire. Among the 360 responses finally included in the analysis, the majority came from radiation oncologists (46%), followed by oncologists. For half of the respondents (53%), indications to perform PET/CT examination were “often” cl...
Abstract: FAPI-based radiopharmaceuticals are a novel class of tracers, mainly used for PET imagi... more Abstract: FAPI-based radiopharmaceuticals are a novel class of tracers, mainly used for PET imaging, which have demonstrated several advantages over [18F]FDG, especially in the case of low-grade or well-differentiated tumors. We conducted this systematic review to evaluate all the studies where a head-to-head comparison had been performed to explore the potential utility of FAPI tracers in clinical practice. FAPI-based radiopharmaceuticals have shown promising results globally, in particular in detecting peritoneal carcinomatosis, but studies with wider populations are needed to better understand all the advantages of these new radiopharmaceuticals.
In the era of precision medicine, the optimization of oncological patient management with early a... more In the era of precision medicine, the optimization of oncological patient management with early and accurate tumor response assessment is crucial. In this scenario, [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has gained an important role in providing prognostically relevant information. The first PET-based scoring system proposed in 1999 was the well-known European Organization for Research and Treatment of Cancer (EORTC) criteria. From that moment on and over the last 20 years, several PET/CT criteria have emerged and have been adapted to enhance the response assessment for specific tumor types and/or therapies, with only a few of them endorsed by guidelines. In this literature systematic review, we aimed to list and discuss the most relevant PET/CT criteria proposed for solid and non-solid [18F]FDG-avid tumors. A literature search extended until November 2022 on the PubMed/MEDLINE database was conducted. The criteria used to assess ...
Background: in recent years, the role of positron emission tomography (PET) and PET/computed tomo... more Background: in recent years, the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide variety of pathological conditions. This review aims to collect and review PET criteria developed for interpretation and treatment response assessment in cases of non-[18F]fluorodeoxyglucose ([18F]FDG) imaging in oncology. Methods: A wide literature search of the PubMed/MEDLINE, Scopus and Google Scholar databases was made to find relevant published articles about non-[18F]FDG PET response criteria. Results: The comprehensive computer literature search revealed 183 articles. On reviewing the titles and abstracts, 149 articles were excluded because the reported data were not within the field of interest. Finally, 34 articles were selected and retrieved in full-text versions. Conclusions: available criteria are a promising tool for the interpretation of non-FDG PET scans, but also to assess the response to therapy and ther...
Uploads
Papers by Giulia Santo